Dabigatran etexilate
- Generic Name
- Dabigatran etexilate
- Brand Names
- Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C34H41N7O5
- CAS Number
- 211915-06-9
- Unique Ingredient Identifier
- 2E18WX195X
- Background
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monit...
- Indication
Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to re...
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Venous Thromboembolism
- Associated Therapies
- -
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 2230
- Registration Number
- NCT04695106
- Locations
- 🇵🇱
Cardiac lntensive Care Unit, First Department of Cardiology, University Clinical Centre in Gdańsk, Gdańsk, Pomorskie, Poland
A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT04257032
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT04208061
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Dabigatran for Mitral Stenosis Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 370
- Registration Number
- NCT04045093
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Ural State Medical University
- Target Recruit Count
- 400
- Registration Number
- NCT03975062
- Locations
- 🇷🇺
Limited Liability Company Medical Association "Novaya Bolnitsa", Ekaterinburg, Russian Federation
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Irina Ermolaeva
- Target Recruit Count
- 200
- Registration Number
- NCT03789695
- Locations
- 🇷🇺
I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT03492437
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 99
- Registration Number
- NCT03240120
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT03237416
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT03217448
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.